SmartViper

xeloda.com domain research


Rating:
4 of 5 (3 votes)
Indexed pages:
11 (3)
Backwards:
806 (24)
Homepage links:
internal 56, external 12
Unique visitors:
364 ( 4)
diff as of April 1, 2012
Title history:
1 changes recorded
HTML validation:
OK
DNS resolve:
OK
Domain worth:
$15,263
Health score:
35.80%

Technical

Website availability: (is site down?)

Latest result: Website is UP

Latest test time and date: 5:48:01 AM May 10, 2014

Latest test duration: 1.186 seconds


Test results (detailed CURL answer)
HTML size: 26006 bytes
Url: http://www.gene.com/patients/medicines/xeloda
Content_type: text/html; charset=UTF-8
Http_code: 200
Header_size: 526
Request_size: 365
Filetime: -1
Redirect_count: 1
Total_time: 1.012333
Namelookup_time: 0.146786
Connect_time: 0.220809
Pretransfer_time: 0.220844
Size_download: 26006
Speed_download: 25689
Download_content_length: 26006
Starttransfer_time: 0.29846
Redirect_time: 0.561467
Used technologies:
Analytics
Google Analytics
Javascript frameworks
jQuery
Modernizr
Miscellaneous
SWFObject
Programming languages
Java
Web frameworks
Java Servlet
Hosting:
GENENTECH (Genentech, Inc.)
Hosting abuse phone:
office +1-650-225-1000
Domain IP:
72.34.128.211 United States (2 changes since February 12, 2010)
IP history:
April 4, 2011 192.12.78.155 → 72.34.128.211
February 12, 2010 207.159.89.179 (Qwest Communications) → 192.12.78.155(GENENTECH)
DNS Resolve:
OK
Domain registrar:
SAFENAMES LTD domain profile
Domains using same registrar:2,478
Name server (NS) records:
hlrns1.roche.com (IP 206.53.227.33)
Other domains using this NS: 53
ns1.roche.com (IP 196.3.50.135)
Other domains using this NS: 53
Public registrar record:

Profile

Unique visitors:
364 ( 4)
diff as of April 1, 2012
Domain age:
17 years and 11 months
Domain worth:
$15,263
Health score:
35.80%
Domain score widget:
Domain worth widget:
Smartviper certification:

Social #xeloda.com

Social activity: updated 17 Jun 2014
Smartviper reviews:
Social Contacts:
phone (888) 835-2555

Advertising

AdSense Checker: (AdSense Checker:)
Is domain banned from using Google Adsense?
Tags prominence:
(important page elements, estimated advertising value)
tell a friend (44%, $1.24), e card (44%, $0.83), colorectal cancer (6%, $2.73), colon cancer (6%, $4.05) (charts and stats)
Ads SERP visibility: based on research of 16,000,000 keywords
Ads position distribution:
This website is not gaining paid search traffic (according to our data updated on 21 April 2012)
Ads visitors:
We detected advertising for this domain only in United States local SERPs.

Geography

Audience location:
Minimum required screen width is 768 - Please use other device to view
SERP organic visitors pie
Visualizes local performance of organic positions. Positions visibility distribution is presented by Country showing each country's share in %

    SEO

    Indexed pages:
    11 (3)
    Backwards:
    806 (24)
    Homepage links:
    internal 56, external 12
    Title history:
    1 changes recorded
    HTML validation:
    OK
    Title:
    Metastatic Breast Cancer, Metastatic Colorectal Cancer, and Adjuvant Colon Cancer Treatment | XELODA® (capecitabine)
    Meta-keywords:
    xeloda, capecitabine, capecitabine chemotherapy, oral chemotherapy tablets, oral chemotherapy, oral chemotherapy for breast cancer, 5 fu chemotherapy, metastatic colorectal cancer treatment, adjuvant chemotherapy colon cancer, metastaticbreast cancer treatment
    Meta-description:
    Official Site for XELODA(R) (capecitabine) tablets for the treatment of metastatic colorectal and breast cancer as well as adjuvant colon cancer treatment. Learn more about XELODA (capecitabine)(R) oral chemotherapy medicine. XELODA is indicated as a single agent for adjuvant treatment in patients with Dukes' C colon cancer who have undergone complete resection of the primary tumor when treatment with fluoropyrimidine therapy alone is preferred. XELODA was non-inferior to 5-fluorouracil and leucovorin (5-FU/LV) for disease-free survival (DFS). Physicians should consider results of combination chemotherapy trials, which have shown improvement in DFS and OS, when prescribing single-agent XELODA in the adjuvant treatment of Dukes' C colon cancer. XELODA is indicated as first-line treatment of patients with metastatic colorectal carcinoma when treatment with fluoropyrimidine therapy alone is preferred. Combination chemotherapy has shown a survival benefit compared to 5-FU/LV alone. A survival benefit over 5-FU/LV has not been demonstrated with XELODA monotherapy. Use of XELODA instead of 5-FU/LV in combinations has not been adequately studied to assure safety or preservation of the survival advantage. XELODA monotherapy is indicated for the treatment of patients with metastatic breast cancer resistant to both paclitaxel and an anthracycline-containing chemotherapy regimen or resistant to paclitaxel and for whom further anthracycline therapy is not indicated, eg, patients who have received cumulative doses of 400 mg/m2 of doxorubicin or doxorubicin equivalents. Resistance is defined as progressive disease while on treatment, with or without an initial response, or relapse within 6 months of completing treatment with an anthracycline-containing adjuvant regimen. XELODA in combination with docetaxel is indicated for the treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing chemotherapy. Boxed WARNING and Contraindications Patients receiving concomitant capecitabine and oral
    Smartviper Domain RSS:
    Get the latest updates on xeloda.com via RSS
    SERP organic visibility: based on research of 16,000,000 keywords
    Domain name is seen on 67 search engine queries. Average position in SERP is 19. Best position in SERP for this domain is #2 (it's found 3 times). Statistical information was collected from April 20, 2012 to April 22, 2012
    SERP organic rankings distribution:
    Visualizes organic positions distribution for domain pages that were found in top 40 results.